Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
While nations and athletes compete briefly on a world stage for Olympic gold, three recent articles in the BMJ remind us that pharmaceutical companies compete across the world for real gold. For instance, the worldwide market for insulin is huge and the papers question the ethics of global pharmaceutical companies. Sanofi-Aventis, Novo-Nordisk, and Eli Lilly have all aggressively marketed a switch to newer forms of insulin that have not proven to achieve better health outcomes than cheaper insulins.
The newest forms of insulin are called ?insulin analogues.? They are genetically engineered forms of insulin that alter the absorption, distribution, and metabolism of insulin. Some insulin analogues are short acting, thereby permit more rapid availability; others are long acting, slowing down release, giving people coverage over an extended period.
http://blogs.scientificamerican.com...ns-discovery-the-worlds-poor-are-still-dying/
The newest forms of insulin are called ?insulin analogues.? They are genetically engineered forms of insulin that alter the absorption, distribution, and metabolism of insulin. Some insulin analogues are short acting, thereby permit more rapid availability; others are long acting, slowing down release, giving people coverage over an extended period.
http://blogs.scientificamerican.com...ns-discovery-the-worlds-poor-are-still-dying/